Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-201 for Detection of Solid Malignancies
NCT03906643Phase 1Withdrawn
- Sponsor
- Herbert Lyerly
- Start
- Jul 2020
- Primary completion
- Jan 2023
- Modality
- Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HS-201 in solid tumor, sponsored by Herbert Lyerly. Primary endpoint: Fluorescence at 1 day. Planned start Jul 2020; status: withdrawn.
02
Drugs
HS-201
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03906643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03906643.